In patients with moderate-to-severe atopic dermatitis (AD), dupilumab was associated with reduced risk of serious or severe infection and non-herpetic skin infections and did not increase overall infection rates when compared to placebo. The analysis pooled data from 7 randomized, placebo-controlled dupilumab trials in participants with moderate-to-severe AD. Exposure-adjusted analyses assessed infection rates. Researchers found:

• Of 2,932 patients, 1,091 received placebo, 1,095 dupilumab 300 mg weekly, and 746 dupilumab 300 mg every 2 weeks.
• Treatment groups had similar infection rates overall per 100 patient-years and similar non-skin infection rates.
• Serious/severe infections were reduced with dupilumab, as were bacterial and other non-herpetic skin infections.